Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
PARP (Poly ADP-Ribose Polymerase) Inhibitor report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is projected to reach US$ 8571.2 million in 2034, increasing from US$ 4686.4 million in 2022, with the CAGR of 8.9% during the period of 2024 to 2034. Demand from Ovarian Cancer and Breast Cancer are the major drivers for the industry.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PARP (Poly ADP-Ribose Polymerase) Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
Ovarian Cancer
Breast Cancer
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PARP (Poly ADP-Ribose Polymerase) Inhibitor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of PARP (Poly ADP-Ribose Polymerase) Inhibitor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, PARP (Poly ADP-Ribose Polymerase) Inhibitor introduction, etc. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of PARP (Poly ADP-Ribose Polymerase) Inhibitor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
PARP (Poly ADP-Ribose Polymerase) Inhibitor report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is projected to reach US$ 8571.2 million in 2034, increasing from US$ 4686.4 million in 2022, with the CAGR of 8.9% during the period of 2024 to 2034. Demand from Ovarian Cancer and Breast Cancer are the major drivers for the industry.
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor key players include AstraZeneca, Tesaro, Merck & Co, etc. Global top three manufacturers hold a share about 90%.
North America is the largest market, with a share about 70%, followed by Europe and Emerging Country, both have a share about 25 percent.
In terms of product, Lynparza is the largest segment, with a share over 65%. And in terms of application, the largest application is Ovarian Cancer, followed by Breast Cancer.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PARP (Poly ADP-Ribose Polymerase) Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
Segment by Application
Ovarian Cancer
Breast Cancer
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PARP (Poly ADP-Ribose Polymerase) Inhibitor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of PARP (Poly ADP-Ribose Polymerase) Inhibitor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the PARP (Poly ADP-Ribose Polymerase) Inhibitor industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, PARP (Poly ADP-Ribose Polymerase) Inhibitor introduction, etc. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of PARP (Poly ADP-Ribose Polymerase) Inhibitor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices